Filter Results:
- Full text PDF available (12)
Publication Year
2004
2018
- This year (8)
- Last 5 years (15)
- Last 10 years (23)
Publication Type
Co-author
Journals and Conferences
Learn More
- Christopher R Chapple, Tomasz Rechberger, +4 authors A. J. M. De Ridder
- BJU international
- 2004
OBJECTIVE
To assess in a phase 3a trial the efficacy of solifenacin succinate, a once-daily oral antimuscarinic agent in development at 5-mg and 10-mg dosage strengths, for the treatment of… (More)
- Paul G. Abrams, Con J. Kelleher, +7 authors A. J. M. De Ridder
- European urology
- 2015
BACKGROUND
Combining the β3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in the treatment of overactive bladder (OAB) while reducing the AM side… (More)
- Christopher R Chapple, Vladimír Dvořák, +8 authors Osamu Yamaguchi
- International Urogynecology Journal
- 2013
Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a… (More)
- Christopher R Chapple, Pedro Arañó, J. L. H. Ruud Bosch, Dirk de Ridder, August E. J. L. Kramer, A. J. M. De Ridder
- BJU international
- 2004
OBJECTIVES
To evaluate the dose-response relationship and safety/tolerability of solifenacin succinate (YM905) in the treatment of overactive bladder (OAB), and to compare its efficacy and… (More)
- Linda Cardozo, david M. Castro-díaz, Marc M Gittelman, A. J. M. De Ridder, Moses Huang
- International Urogynecology Journal
- 2005
The embarrassment and social stigma associated with urinary incontinence (UI) in overactive bladder syndrome (OAB) sufferers is a major reason for individuals to seek help for their condition. An… (More)
- François Haab, Linda Cardozo, Christopher Key Chapple, A. J. M. De Ridder
- European urology
- 2005
OBJECTIVE
To examine safety and tolerability findings as primary endpoints, and efficacy outcomes as secondary endpoints, of solifenacin treatment over a period of up to 1 year. Long-term efficacy in… (More)
- Linda D. Cardozo, M Lisec, +5 authors A. J. M. De Ridder
- The Journal of urology
- 2004
PURPOSE
In this phase 3 trial we assessed the efficacy of solifenacin 5 mg and 10 mg daily in patients with symptoms related to overactive bladder. In addition, we assessed the safety and… (More)
- Con J. Kelleher, Linda Cardozo, Christopher R Chapple, François Haab, A. J. M. De Ridder
- BJU international
- 2005
OBJECTIVE
To assess the effect of solifenacin succinate treatment on quality of life (QoL) measured in clinical trials in patients with overactive bladder (OAB).
PATIENTS AND METHODS
QoL data using… (More)
- Heshu Abdullah-Koolmees, T. Gerbranda, +4 authors Eibert Roelof Heerdink
- European Journal of Clinical Pharmacology
- 2012
Continuation of coumarin therapy is important to prevent thromboembolic events. Continuation of medication, unrelated to the reason for hospital admission, may be at risk due to the patient’s… (More)